Stock Analysis
Eli Lilly and Company (LLY) Stock Analysis
Eli Lilly and Company (LLY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Eli Lilly and Company (LLY) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 95/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
LLY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $1,270.75 |
| AIQ Score | 62/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $1.09T |
| P/E Ratio (TTM) | 38.86 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $7.95 |
| Revenue (quarter ended 2026-06-30) | $22.97B |
| Dividend Yield (TTM) | 0.58% |
| Beta | 0.51 |
| Volume | 1.88M |
| 52-week range | $793.82-$1,311.75 |
| RSI 14 | 72.85 |
| 50-Day SMA | $1,183.59 |
| 200-Day SMA | $1,082.90 |
| Analyst Price Target | $1,328.15 |
| Next Earnings | Oct 29, 2026 |
LLYEli Lilly and Company
Healthcare / Drug Manufacturers - General
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum95
- Value26
- Quality76
- Risk resilience50
- Sentiment74
LLY Stock Analysis Summary
Eli Lilly and Company (LLY) currently has an AIQ Score of 62/100, indicating a neutral setup. Momentum is the strongest factor at 95/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, LLY has AIQ Score of 62/100 with Momentum base of 95/100 and fading Value at 26/100. Wait for component alignment before adding exposure.
Momentum (95/100) leads while Value (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.01% stock move · LLY classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is LLY Bullish or Bearish Right Now?
LLY currently has a neutral overall setup. Momentum is the strongest factor at 95/100, while Value is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 76/100.
- - Momentum is constructive at 95/100.
- - Price is +7.36% above its 50-day SMA.
- - Analyst target implies +4.52% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 5).
- - Value is the current constraint at 26/100.
Current Consensus
LLY's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 4 neutral, and 5 sell votes. LLY's 14-day RSI is 72.85, which places the stock in an overbought momentum range. LLY's beta is 0.51, indicating lower market sensitivity than the broad market.
What Changed in LLY?
The largest recent change in LLY is Momentum moving up by 13.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the LLY Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
LLY Decision Framework
Public evidence layers, setup checks, and risk context for Eli Lilly and Company.
Eli Lilly and Company (LLY) Stock Analysis
Eli Lilly and Company has an AIQ Score of 62/100 in a Neutral regime. Momentum is strongest at 95/100. Beta is 0.45, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | LLY is in a Neutral AIQ regime with score 62/100. |
| Signal Conflict | The primary conflict is that momentum leads at 95/100 while value lags at 26/100. |
| Factor Evidence | Momentum 95/100 · Value 26/100 · Quality 76/100 · Risk 50/100 · Sentiment 74/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 95/100.
Momentum is 95/100 and RSI (14) is 72.8.
LLY is in a Neutral regime at 62/100.
Risk factor is 50/100 with beta 0.45 and annual volatility 34.89%.
Current conflict: momentum leads at 95/100 while value lags at 26/100.
LLY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
LLY Fundamentals
LLY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
LLY Technical Analysis
LLY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
LLY Stock Catalysts
Track LLY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
LLY Dividend Analysis
LLY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
LLY Financial Data
LLY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
LLY Risk Analysis
LLY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
LLY Stock News
LLY stock news, market tone, recent headlines, and catalyst context.
LLY vs Large-Cap Pharma Peers
Current peer cohort: LLY · NVO · JNJ · ABBV · MRK. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| LLY Current stock | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | Current |
| NVO Novo Nordisk | 67/100 | 60/100 | 56/100 | 51/100 | -0.63 | 45.71% | LLY vs NVO |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | LLY vs JNJ |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | LLY vs ABBV |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | LLY vs MRK |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular LLY Comparisons
How LLY scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching LLY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for LLY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
LLY Stock FAQ
What is LLY stock price today?
Eli Lilly and Company's current stock price is $1,270.75. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is LLY bullish or bearish right now?
LLY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is LLY's market cap?
LLY's market cap is $1.09T based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is LLY's current P/E ratio?
LLY's current P/E ratio is 38.86 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is LLY's RSI?
LLY's 14-day RSI is 72.85 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is LLY above its 50-day and 200-day moving averages?
LLY is 7.36% from its 50-day SMA and 17.35% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is LLY's next earnings date?
LLY's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does LLY pay a dividend?
LLY's dividend yield is 0.58% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.